Antibiotic Stakeholders Discuss Ethics Of Testing Limited Population Drugs In Broader Populations
The US FDA's LPAD draft guidance suggests that clinical trials for potential limited population antibacterials would enroll broader patient populations. But is that an ethical approach?
